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Abstract
Nakoa Kristen Webber
IDENTIFYING INHIBITORS TARGETING THE NONSTRUCTURAL PROTEIN 15
AND MAIN PROTEASE OF CORONAVIRUSES USING MOLECULAR DOCKING
AND MOLECULAR DYNAMICS SIMULATION
2020-2021
Nathaniel V. Nucci Ph.D
Master of Science in Bioinformatics

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) in 2020 has impacted daily life globally for over a year. While multiple vaccines
have been authorized for emergency use and one oral medication has entered clinical
trials, we are still seeking antiviral drugs for a long-term treatment for SARS-CoV-2 as
well as other coronaviruses. Computational drug screenings of two SARS-CoV-2 protein
target candidates are presented in this thesis: the nidoviral RNA uridylate-specific
endoribonuclease (Nsp15) and the main protease (Mpro) of SARS-CoV-2. Nonstructural
proteins of coronaviruses were selected as targets as they are more conserved across
coronavirus strains than structural proteins. High throughput virtual screening of small
molecule libraries including DrugBank and ZINC 15 resulted in several promising
compounds for each of these targets. Molecular dynamics simulation allowed us to
predict the binding energies for these compounds using molecular mechanics with
generalized born surface area solvation calculations (MM-GBSA). Four top compounds
were discovered for Nsp15 and eight compounds for Mpro.
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Chapter 1
Introduction
Coronaviruses
Coronaviruses are pathogens which target the respiratory system of both humans
and animals (Shereen et al., 2020). The coronaviruses known to infect humans are all
zoonotic in nature (Latinne et al., 2020). Currently, there are seven known human
coronaviruses (H-CoVs) (Shereen et al., 2020). Most H-CoVs have origins in bats, with
the exception of beta-CoVs, which are thought to originate from rodents (Forni et al.,
2017). The most common and pathogenic coronaviruses that threaten human life are
severe acute respiratory syndrome (SARS-CoV), middle east respiratory syndrome
MERS-CoV, and SARS-CoV-2 (Liu et al., 2020).
Zoonotic viruses such as SARS-CoV2 remain a threat to public health as they all
have potential to evolve into pandemics. There are two key factors that lead a virus to
become a pandemic. First, the virus must be introduced into a population (Santacroce et
al., 2020). Humans are exposed to a new virus through contact with blood, feces, saliva,
food, or water contamination, or via an arthropod such as a mosquito or a tick
(Woolhouse et al., 2012). Next, the virus must spread and maintain itself throughout that
population (Santacroce et al., 2020). Virus spread is measured by a Ro value. A Ro greater
than 1 indicates that a single case leads to more than one additional case (Woolhouse et
al., 2012). Transmission of the virus through a population depends on how infectious the
host is the duration of infectability, and the behavior of the infected population
(Woolhouse et al., 2012). The most recent impactful coronaviruses (SARS-CoV, MERS1

CoV, and SARS-CoV-2) had Ro values of 2.9, 1.3 and 5.7 prior to public intervention
(Sanche et al., 2020) (Liu et al., 2020). Social distancing efforts to prevent the spread of
coronaviruses by lowering Ro values is disruptive and devastating to local economies.
Further understanding of these viruses and efficacious methods of treatment will directly
save lives. We hope to be prepared should the world be faced with a similar (or worse)
pandemic in the future.
SARS-CoV, MERS-CoV, and SARS-CoV-2
Coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 are structurally and
genetically conserved. Each virus is a positive-sense, single-stranded RNA virus
(Alexandersen et al., 2020). While most RNA viruses tend to lack the 3’ exonuclease
proofreading capabilities that make DNA viruses less error-prone, Coronaviruses contain
a 3’ exonuclease domain found in Nsp14 (Sanjuán & Domingo-Calap, 2016). The
function of this exonuclease is likely responsible for the maintenance of a genome of this
size (Robson et al., 2020). The genomes of coronaviruses contain approximately 30,000
nucleotides with the majority of the genome coding for the replicase gene of the
coronavirus (Sanders et al., 2021). The replicase gene consists of two open reading
frames (ORF), ORF1a which encodes for polyprotein (pp) 1a and ORF1b. ORF1a and
ORF1b encode for polyprotein pp1ab together. These polyproteins are cleaved into 16
nonstructural proteins (Nsps) by the chymotrypsin-like (Mpro) and papain-like (PLpro)
proteases. The PLpro cleaves at five sites, working in the N-terminal direction, Nsp1-4.
The Mpro, which is Nsp5, cleaves the polyprotein at eleven sites working in the Cterminal direction. Mpro auto-cleaves itself from the polyprotein, then cleaves Nsp6-16
(Sanders et al., 2021) (Figure 1).
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Figure 1
Replication Cycle of SARS-CoV2

Note. In the replication cycle of SARS-CoV-2, viral RNA is released into the cell. From
the RNA viral genome, ORF1a and ORF1b are translated into polyproteins pp1a and
pp1ab. To begin the cleavage of nonstructural proteins, the Mpro first cleaves itself.
Nonstructural proteins next combine to begin the replication process (Sanders et al.,
2021).

Structural Proteins of SARS-CoV2
There are four main structural proteins within SARS-CoV2: a spike glycoprotein,
small envelope glycoprotein, membrane glycoprotein, and a nucleocapsid protein (Astuti
& Ysrafil, 2020). The spike glycoprotein is a transmembrane protein approximately 150
kDa in size and is located on the outside of the virus structure (Astuti & Ysrafil, 2020).
The spike protein is responsible for host-virus attachment. Small envelope glycoproteins
form homotrimers within the viral surface which facilitate binding of envelope viruses to
3

host cells by attracting angiotensin-converting enzyme 2 (ACE2) (Astuti & Ysrafil,
2020). The small envelope glycoprotein is cleaved by a host cell furin-like protease into
S1 and S2 (Astuti & Ysrafil, 2020). The S1 subunit contains a receptor-binding domain
which recognizes and binds to the host receptor angiotensin-converting enzyme 2 (Huang
et al., 2020). The S2 subunit forms a six-helical bundle that plays a role in mediating viral
cell membrane fusion (Huang et al., 2020).

Figure 2
Structural Proteins of SARS-CoV2

Note. The structural proteins of SARS-CoV2 include nucleocapsid proteins, membrane
glycoproteins, spike glycoproteins, and envelope proteins. The spike protein is shown in
this figure interacting with ACE2 for host attachment (Saxena et al., 2020).
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Nonstructural Proteins of SARS-CoV2
The nonstructural proteins of SARS-CoV2 play an important role in genome
replication and transcription of the virus (Gasmalbari & Abbadi, 2020). Each Nsp plays a
role in virus infection or replication as shown in Table 1. Nsp’s are promising targets for
vaccines and medications as targeting one or more can reduce or halt viral replication.
Most nonstructural proteins have conserved amino acid sequences among different
coronaviruses which would allow one drug to target them all.

Table 1
Nonstructural Proteins of Coronaviruses and their Function
NSP1

Suppresses host gene expression by degrading the host cell’s RNA (Sanders et al., 2021),
prevents hosts cells from performing antiviral functions (Gasmalbari & Abbadi, 2020)

NSP2

Thought to play a crucial role in viral RNA synthesis (Sanders et al., 2021), the specific
mechanism of action requires further research

NSP3

Papain-like protease (Plpro) protein responsible for processing of the viral polypeptide
(Cornillez-Ty et al., 2009)

NSP4

Required for viral replication by assembly of, and localizing to, double-membrane
cytoplasmic vesicles (with nsp3) (Sakai et al., 2017)

NSP5

Mpro (3CL), main protease, cleaves at 11 sites (Zhang et al., 2020)

NSP6

Induces double membrane vesicles, interferes with delivery of viral factors to lysosomes for
destruction (Angelini et al., 2013)

NSP7

Forms a super complex with NSP8, works as a cofactor for the RNA-dependent RNA
polymerase nsp12 (Snijder et al., 2016)

NSP8

Forms a super complex with NSP 7 that supports viral replication works as a cofactor for the
RNA-dependent RNA polymerase nsp12 (Snijder et al., 2016)
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NSP 9

Plays a role in the binding of ssRNA and dsDNA and affects viral growth (Sanders et al.,
2021)

NSP 10

Forms a part of the viral mRNA cap methylation complex (Sanders et al., 2021)

NSP 11

Function of NSP 11 is unknown

NSP 12

Responsible for priming the dependent RNA polymerase (Sanders et al., 2021)

NSP 13

A helicase with RNA and DNA unwinding capabilities, possesses dNTPase activity, helping
form the 5’ cap of viral mRNA (Sanders et al., 2021)

NSP 14

Responsible for proofreading during RNA replication and viral mRNA capping (Snijder et
al., 2016)

NSP 15

Processes viral RNA, aids in evasion of hosts defense system (Hsu 2021)

NSP 16

Adds Nsp10 and Nsp14 to form the mRNA cap methylation complex. (Sanders et al., 2021)

Current Variants of SARS-CoV-2
As of June 2021, there are currently seven variants of interest of novel SARSCoV-2: B.1.525 originally detected in the United Kingdom/Nigeria (2020), B.1.526 and
B.1526.1 originally detected in the United States (2020), B.1617, B.1.617.1, and
B.1.617.3 originally detected in India (2021 and 2020), and P.2 originally detected in
Brazil (2020) (CDC). A variant is classified as of interest if it contains genetic markers
that have been associated with changes to receptor binding, reduced neutralization by
antibodies generated against previous infection or vaccination, reduced efficacy of
treatments, potential diagnostic impact, or predicted increase in transmissibility or disease
severity (CDC 2020).
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According to the CDC there are currently 6 variants of concern: B.1.1.7 originally
detected in UK(2020), B.1.351 originally detected in South Africa (2020), B.1.427 and
B.1.429 originally detected in the US (2021), B.1.617.2 originally detected in India
(2020), and P.1 originally detected in Japan/Brazil (2021). A variant is considered to be
of concern when there is evidence of increased transmissibility, increased severity of
disease, significant reduction in neutralization by antibodies generated during previous
infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic
detection failures (CDC 2020).
In silico Screening for a SARS-CoV-2 Inhibitor
Lack of treatment or vaccine for SARS CoV-2 led to extreme loss of life and
economic disruption in the years 2020 and 2021 (V’kovski et al., 2020). Scientists from
all over the world are searching diligently for an effective inhibitor-target duo to lessen
the severity of this virus (V’kovski et al., 2020). One beneficial starting point in the
search for a potential drug suitable as a specific inhibitor for SARS-CoV-2 is in silico
screening (Chandra et al., 2020). When searching for potential inhibitors for SARS-CoV2, researchers are initially screening previously developed compounds in libraries
including the Food and Drug Administration (FDA) approved drug database for structure
based virtual screening (SBVS) as well using molecular docking to compare drugs that
are used in the treatment of other viruses (Chandra et al., 2020). The first strategy is
designing the compound based on the existing broad spectrum of antivirals. The
advantage of this approach is that the established pharmacological properties for these
compounds allow them to be readily used (Baby et al., 2021). The downside to this
strategy is the limitation of available compounds within the library search.
7

In our study, we investigated small molecules and their potential to inhibit Nsp15
and the Mpro (Nsp 5) of SARS-CoV2 using in-silico screening. Targeting Nsp proteins
for inhibition as opposed to the structural proteins of coronaviruses is advantageous due
to strong conservation across viral strains. The spike protein, for example, is highly
mutagenic (Zhou et al., 2021). All variants of SARS-CoV-2 (as classified by the CDC)
contain spike protein amino acid substitutions. In a study by Khan et al, a multiple
sequence alignment was performed comparing sequences of the SARS-CoV-2 Mpro from
thirteen different countries. From these alignments, only a single point mutation was
found from the Vietnam strain (Khan et al., 2020). There are no known mutations of the
Nsp15 protein in any of the new SARS-CoV-2 strains (CDC 2020). Our objective is to
find an inhibitor not only for SARS-CoV2, but one with potential to treat its variants and
future coronaviruses as well.
Nonstructural Protein 15 of SARS-CoV2
NSP 15 is a nidoviral RNA uridylate-specific endoribonuclease (NendoU). Nsp
15 contains a carboxy-terminal catalytic domain that functions by cleaving RNA at the
3′-position of uridylates to form a 2′-3′ cyclic phosphodiester product (Chandra et al.,
2020). The structure of Nsp15 is 84.38 kDa in size (Kim et al., 2020). The C- terminal
NendoU domain contains two antiparallel β-sheets (β16–β17–β18 and β19–β20–β21)
with the active site between them. The active site carries six key residues which are
conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV coronaviruses (figures 3
& 4) : His235, His250, Lys290, Ser 294, Thr341, Tyr343) and is thought to play a role in
processing viral RNA as well as aiding in the evasion of host defense mechanisms (Kim
et al., 2020).
8

Figure 3
Active Site Overlay of Nsp 15 of SARS-CoV, MERS, SARS-CoV-2

Note. An active site overlay of Nsp 15 of SARS-CoV2 (teal) SARS (pink), and MERS
(grey) shows structural similarity among these Coronaviruses. Key residues involved in
ligand binding (His235, His250, Lys290, Ser294, Thr341, and Tyr343) are highlighted
(Kim et al., 2020).

While its exact function is unclear, conservation among coronaviruses, confirmed
by multiple sequence alignment presented in Figure 4, suggests that Nsp15 is essential
for viral replication. Previous studies suggest that there are multiple Nsp15 cleavage
targets that are important to regulate the accumulation of viral RNA and prevent
activation of RNA-activated antiviral responses (Pillon et al., 2021) (Ancar et al., 2020).
By targeting this protein with a small molecule inhibitor, we can disrupt the viral
replication process or potentially prevent the evasion of the body’s immune response to
the virus.

9

Figure 4
Multiple Sequence Alignment of Nsp15 of SARS, MERS, and SARS-CoV2

Note. Amino acid multiple sequence alignment of Nsp15 of SARS, MERS, and SARSCoV2 performed using T-Coffee (Notredame et al., 2000). Amino acids highlighted in
black are conserved among SARS, MERS, and SARS-CoV2. Individual amino acids
highlighted in grey show amino acids with similar characteristics or properties to those in
the same position on different coronaviruses. Figure created using BoxShade
(https://embnet.vital-it.ch/software/BOX_form.html).

Main Protease of SARS-CoV2
The Mpro (also referred to as 3CLpro) was selected due to its significant role in
viral replication by processing polypeptides after translation from viral RNA (Zhang et
al., 2020). This enzyme is ~34 kDa in size (Kneller et al., 2020). The Mpro’s function is
cleaving 11 sites on polyprotein 1ab to continue the replication cycle which suggests
inhibition would block replication by preventing cleavage of non-structural proteins from
pp1a and pp1ab (Zhang et al., 2020) (Sanders et al., 2021). As one of the most
10

characterized targets of the SARS-CoV2 virus, the Mpro displays high genetic and
structural conservation with earlier coronaviruses with no human analogues (Mengist et
al., 2021). A multiple sequence alignment shown in Figure 5 confirms the conserved
amino acid sequence of the Mpro across coronaviruses SARS, MERS, and SARS CoV2.

Figure 5
Multiple Sequence Alignment of Mpro of SARS, MERS, and SARS-CoV2

Note. Amino Acid multiple sequence alignment (MSA) of the Mpro of SARS, MERS,
and SARS CoV2. Amino acids highlighted in black are conserved among SARS, MERS,
and SARS-CoV2. Individual amino acids highlighted in grey show amino acids with
similar characteristics or properties to those in the same position on different
coronaviruses. MSA performed by T-Coffee (Notredame et al., 2000). Figure created
using BoxShade.

11

Structurally, the Mpro is functional as a homodimer with each monomer
consisting of three domains (Sanders et al., 2021). The active site is formed by
antiparallel beta sheets from domains I (residues 1-101) and II (residues 102-184)
containing a Cys-His dyad (Figure 6 A, B). Eight residues (Ser 46, leu141, Asn 142, Glu
166, Pro168, Ala191, Thr190, and Gln189) surround the active site and play roles in
ligand binding (Figure 6 B). Domain III (residues 185-200) contains five alpha helices
and facilitates dimerization (Kneller et al., 2020) (Verschueren et al., 2008). Dimerization
is essential for function as the monomer is not catalytically active (Kneller et al., 2020).

Figure 6
Active Site of Mpro

Note. The three-dimensional structure of the SARS-CoV-2 Mpro. A. The dimerized Mpro
is shown with one monomer in orange and the other (containing the catalytic domain) is
shown in teal. B. The catalytic site of Mpro is shown with the catalytic dyad of Cys145
and His41 colored purple. Nearby residues interacting within the binding pocket are
shown in green. (Figure created by Kneller et al., 2020 and is used under Creative
12

Commons Attribution 4.0 International License
https://creativecommons.org/licenses/by/4.0/legalcode).

First Small Molecule Inhibitor Targeting Mpro
Pfizer recently announced its first antiviral small molecule inhibitor targeting the
Mpro of SARS-CoV2, PF-07321332. This inhibitor is currently in Phase 1 clinical trials
(NCT04535167) and is delivered orally (Halford, 2020). Scientists originally discovered
this compound in an attempt to target SARS in 2002, and with most targets of
coronaviruses remaining structurally conserved, they began testing this compound for
SARS-CoV2. Early data suggests that compound PF-07321332, which is a prodrug,
releases active antiviral compound PF-00835231in tissue (Halford, 2020). PF-00835231
exhibits antiviral activity in multiple strains of SARS-CoV2 as well as other
coronaviruses suggesting the possibility of a broad spectrum therapeutic for
coronaviruses (Halford, 2020). Currently, the projected effective dose of this proposed
inhibitor is 500mg/day delivered intravenously which is considered high.
Conclusion
With its first small molecule inhibitor in clinical trials, the Mpro of coronaviruses
remains a promising drug target. We continue to search for to a small molecule inhibitor
for the Nsp15 of Coronaviruses. Structures of these key proteins involved in coronavirus
replication are well characterized making them a prime candidate for high throughput
virtual screening to discover an inhibitor. Using high throughput virtual screening,
molecular docking, and molecular dynamics simulation, we have presented several
promising compounds from the Zinc15 library targeting the NSP15 and Mpro proteins.
13

Chapter 2
Methods
Introduction
In Silico high-throughput virtual screening provided us with a method to search
for compounds with potential to bind favorably to our protein targets (Nsp15 and Mpro)
for inhibition. Because the Nsp15 and the Mpro structures are well characterized, we
were able to prepare their structures from PDB files 6WXC and 6LU7 respectively in
maestro for molecular docking. Using pharmacophore screening of each protein’s natural
ligand, we searched the FDA approved drug bank, Zinc15 library, and the
SwissSimilarity library for compounds with structural similarities to each natural ligand
(Zoete et al., 2016). Following the workflow presented in Figure 7, compounds were
narrowed down to top candidates which were first docked using Glide docking in
Maestro. Top candidates were then induced fit docked to each target protein where those
with the best docking scores were evaluated by molecular dynamics (MD) simulations.
The molecular mechanics generalized Born surface area solvation calculation (MMGBSA) was used to predict the binding energy of each ligand to the Nsp15 and Mpro.
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Figure 7
High Throughput Virtual Screening Workflow

Note. High throughput virtual screening workflow starting with protein structure
preparation using Maestro, compound search of three different libraries, molecular
docking to identify hit compounds, and finally, molecular dynamics simulation.

Multiple Sequence Alignment
Multiple sequence alignment (MSA) of the amino acid sequences of the Nsp15
and Mpro of SARS, MERS and SARS-CoV2 was performed using T-Coffee (Notredame
et al., 2000). MSA allowed us to confirm structural conservation of key residues involved
in binding among these different coronaviruses.
Protein Structure and Receptor Grid Preparation
The structures of Nsp 15 and of Mpro were retrieved from the Protein Data Bank
as PDB ID: 6WXC 6LU7, respectively. The protein structure was prepared for molecular
docking using the Maestro protein preparation wizard (Madhavi Sastry et al., 2013).
15

Water molecules beyond 5 Å from the surface of each protein were deleted, and both
proteins were optimized at pH 7.0. The optimized proteins were subject to a restrained
minimization to relax the protein structure using an OPLS3 force field. The active site
was located by the center of the natural ligand for receptor grid preparation.
Ligand Preparation
The three-dimensional ligand structures were prepared using Maestro Elements
2.2, a feature within the Maestro 10.2 software. Ionization/tautomeric states were
generated at pH =7 using EPIK which employs the refined Hammett and Taft method
(Madhavi Sastry et al., 2013). The lowest ionization/tautomeric state was selected. The
ligand structure was relaxed via restrained minimization in Maestro.
Glide Docking of the Natural Ligand
The natural ligand of both Nsp15 and the Mpro of SARS-CoV2 was first docked
using Glide dock. Docking the natural ligand back to the protein allows us to validate our
docking methods. Glide XP docking searches for the most favorable ligand-receptor
conformations for a protein-drug complex. Standard Glide dock was used to dock each
crystal ligand into its respective receptor grid under default parameters.
High Throughput Virtual Screening: Zinc Drug-Like Library
To search for promising small molecule inhibitors, virtual libraries were searched
using the natural ligand as a model for structure similarity. Libraries included within the
search for Nsp15 inhibitors were SwissSimilarity, DrugBank, and Zinc15 (Sterling &
Irwin, 2015). The library searched for Mpro inhibitors was Zinc15. Initial screening of
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over 7 million compounds presented several promising compounds with structural
similarity to the natural ligand for both protein targets.
QikProp ADME Filtering of Compounds
QikProp from Schrodinger was used as an ADME (absorptions, distribution,
metabolism, excretion) filter to quickly reduce molecular candidates which fall outside of
the normal range of known drug limits of properties such as molecular weight, logP
value, .and oral absorption.
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Figure 8
Workflow of Virtual Screening Compounds for Inhibition of Coronaviruses

Note. Workflow of virtual screening compounds for inhibition of coronaviruses

Glide Docking
Promising molecules for inhibition were docked to the prepared Nsp15 (PDB:
6WXC) (Kim et al., 2020) and Mpro (PDB:6LU7) (X. Liu et al., 2020) protein structures
using the Glide feature of Maestro software. Glide is a quick and rigid method of
molecular docking which calculates a docking score based on protein-ligand coulombvdW energy with a small contribution from GlideScore (Friesner et al., 2004). The
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GlideScore is a value meant to separate molecules with strong versus weak binding
potential (Friesner et al., 2004). While the docking scoring function used by Glide is
proprietary, we do know it rewards Van der Waals and Coulomb energy contributions,
hydrophobic terms, hydrogen bonds, and polar interactions within the binding site. Glide
penalizes the inhibition of rotatable bonds and other binding interactions (Friesner et al.,
2006). Molecules with docking scores greater than the score of the natural ligand were
considered for further evaluation. Compounds with high structure similarity were
eliminated to diversify the screening.
Induced Fit Docking
Induced fit docking was performed on the top 19 compounds of Nsp15 and top 30
compounds of Mpro to validate top compounds by allowing conformational changes
within the binding pocket of the protein. Induced fit docking files were ordered by
highest docking score and processed for molecular dynamics simulation.
Molecular Dynamics Simulation
Molecular dynamics simulations were performed using Desmond Molecular
Dynamics simulation by Schrodinger. Molecular dynamics allows us to observe how
compounds may bind to a protein target by estimating kinetics and binding energy. Each
system was solvated in an orthorhombic water box using the SPC water model with a 10
Å water buffer (Mark & Nilsson, 2001). To neutralize the systems, Na+ ions were added
with a salt concentration of 0.15 M NaCl. After successful solvation of each system, the
OPLS3 force field (Harder et al., 2015) was used to represent the receptor-ligand
complex. For each system, the default relaxation protocols were followed in the
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Desmond simulation package (Jorgensen et al., 1996). Simulations were run for 200
nanoseconds at a temperature of 300 K.
Protein and Ligand Root-Mean-Square Deviation of Atomic Position (RMSD)
Calculation
Root mean square deviation calculations were performed for both the protein and
ligand for conformation of binding stability throughout the simulation using equation 1:

RMSD = √

1

𝑁

′
2
∑𝑁
𝑖=1 (𝑟𝑖 (𝑡𝑥 )) − 𝑟𝑖 (𝑡𝑟𝑒𝑓 )) )

(1)

Where N is the number of atoms in the atom selection; tref is the reference time, (the first
frame is used as the reference as time t=0); and ri' is the position of the selected atoms in
frame x after superimposing on the reference frame, where frame x is recorded at time tx.
This calculation is repeated for every frame in the simulation trajectory.
Protein RMSD values were expected to stabilize toward the end of each
simulation which indicated a steady state within the binding pocket. Ligand RMSD
values significantly larger than the protein RMSD suggest the ligand has likely moved
from the binding site.
Protein Root Means Square Fluctuation (RMSF) Calculation
Protein RMSF was calculated to determine individual amino acid changes
throughout the simulation. RMSF was calculated using equation 2:
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RMSF = √

1

𝑇

∑𝑇𝑡=1 < (𝑟𝑖′ (𝑡 )) − 𝑟𝑖 (𝑡𝑟𝑒𝑓 ))2 ) >

(2)

Where T is the trajectory time over which the RMSF is calculated, tref is the reference
time, ri is the position of residue i; ri' is the position of atoms in residue i after
superposition on the reference, and the angle brackets indicate that the average of the
square distance is taken over the selection of atoms in the residue.
Binding Energy Calculation
Molecular Mechanics-General Born Surface Area (MM-GBSA) binding energies
were calculated for the last 10 nanoseconds of the combined trajectory for each system
where the RMSD calculation suggested binding stability within the system. This method
of binding energy prediction was selected as it balances accuracy and computational
power. The OPLS3 force field, VSGB 2.0 solvation model (Li et al., 2011) and the
default prime protocol (Cournia et al., 2017) was used to separately minimize the
receptor, ligand, and receptor-ligand complex using equation 3 for the total binding free
energy:
ΔG(bind) = Ecomplex (minimized) – (Eligand (minimized) + Ereceptor (minimized))

(3)

Binding components (Coulombic + H-bond + GB solvation+ van der Waals + π-π
packing + self-contact + hydrophobic) were evaluated into separate groups: Eelectrostatic,
EvdW, and Ehydrophobic, where (Eelectrostatic = Ecoulombic + EH-bond + EGB-solvation) and (EvdW =
EvdW + Epi-pi stacking + Eself-contact).
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Simulation Interaction Diagram Analysis
The Simulation Interaction Diagram in Desmond and Glide was used to view
interactions between the protein and ligand in each simulation. Residues interacting with
the protein for at least 30 % of the simulation are highlighted. 2D interaction diagrams
are included for proteins and compounds simulated in Figures 13 and 18.
ADME Property Prediction
Predicted ADME (absorption, distribution, metabolism, and excretion) properties
were evaluated using the Swiss ADME server (http://www.swissadme.ch) to determine
the potential for any compounds to be functional as a drug from pharmacokinetic and
physicochemical properties (Daina et al., 2017).
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Chapter 3
Molecular Docking and Molecular Dynamics Simulation of Inhibitors Targeting
Nsp15
Introduction
The Nsp15 protein of Coronaviruses plays a key role in viral replication making it
a potential target for a small molecular inhibitor. In this chapter, I present the results of
our high throughput virtual screening of small molecule libraries including DrugBank
and ZINC 15. Four promising compounds were identified for Nsp15. Molecular
dynamics simulation allowed us to predict the binding energies (calculated by MMGBSA) for these compounds and further understand the interactions supporting binding.
Using the SwissADME server we were able to identify structurally based ADME
properties that determine the likelihood of our compounds to perform successfully as
drugs.
Molecular Docking
Natural Ligand Docking
Using Glide docking software in Maestro, we measured the binding score of the
natural ligand of Nsp15 to validate our docking protocol (Figure 9). The binding score of
the natural ligand docked to the binding site of PDB:6LU7 was calculated at -7.295
kcal/mol. When evaluating compounds for molecular docking, we searched for
compounds with preliminary docking scores better (more negative) or equivalent to this
value.
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Figure 9
NSP15 Complex with its Natural Ligand and 2D Structure

Note. A. Nsp15 is shown in complex with its natural ligand (PDB:6WXC). B. The twodimensional structure of the natural ligand of Nsp15 is presented.

Glide and Induced Fit Docking
Molecules from the high throughput virtual screening of the DrugBank and
Zinc15 databases were docked to NSP15 using GlideXP. Compounds found to have an
initial docking score greater than or equal to the docking score of the natural ligand were
selected for further evaluation by induced fit docking. Compounds with high structure
similarity to each other were eliminated to diversify the screening.
Nineteen compounds from the Zinc15 database were selected for further
consideration because their docking scores ranged from -7.33 kcal/mol to -10.32
kcal/mol. The docking score allows us to easily compare binding probability among
compounds. No targets were selected for further evaluation from the DrugBank library
due to low docking scores. An induced fit docking protocol as described in Chapter 2,
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was employed to optimize the docking pose of those compounds for molecular dynamics
simulation.
Molecular Dynamics Simulation
Molecular dynamics simulation was performed as described in Chapter 2 to
further evaluate binding of hit compounds to NSP15. Output of the MD simulations
included docking scores from the previous induced fit docking, MM-GBSA free energy,
and RMSD values for the protein and ligand. The RMSD value for each compound
averaged over the last 20 ns of the simulation was presented. The last 20 ns were
averaged as we expected the complex to be stable for this portion of the simulation.
Results of these simulations are presented in Table 2.
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Table 2
Properties of the Top 19 Compounds were Determined from Molecular Docking
and MD Simulations

Zinc ID

Docking Score
(kcal/mol)
-7.295

MM-GBSA
(kcal/mol)
-28±2.7

Receptor
RMSD1 (Å)
1.67±0.1

Ligand
RMSD1 (Å)
4.48±1.0

ZINC000013545806

-10.327

-67.3±5.3

3.14±0.3

22.73±3.7

ZINC000004096690

-10.007

-21.0±4.5

2.87±0.3

44.93±6.8

ZINC000247434422

-9.799

-76.5±6.7

4.07±0.5

7.97±0.4

ZINC000004095545

-9.758

-2.7±3.3

2.78±0.7

44.56±8.6

ZINC000030690671

-9.267

-28.7±13.0

2.63±0.3

45.52±7.7

ZINC000004096060

-9.067

-6.6±3.2

6.44±0.6

46.49±6.8

ZINC000043898683

-8.666

-38.3±16.7

2.52±0.2

12.49±3.8

ZINC000043772626

-8.168

-47.5±9.7

3.19±0.3

5.19±2.5

ZINC000257311522

-7.708

-41.1±10.0

2.35±0.1

24.65±7.5

ZINC000002573902

-7.66

-33.8±4.6

4.1±0.4

13.2±1.1

ZINC000097814854

-7.633

-40.0±9.0

2.2±0.3

6.92±0.8

ZINC000005811925

-7.585

-19.8±6.9

2.7±0.3

21.0±0.9

ZINC000095447896

-7.478

-30.5±9.9

2.4±0.2

15.9±6.5

ZINC000033902452

-7.478

-49.0±3.3

2.7±0.2

3.0±0.5

ZINC000044020013

-7.463

-50.0±3.0

2.7±0.3

7.4±1.0

ZINC000584892418

-7.461

-28.3±3.8

3.1±0.3

21.3±1.1

ZINC000257288396

-7.423

-36.0±9.0

4.5±0.5

36.25±10.7

ZINC000009716294

-7.388

-39.1±8.1

2.8±0.3

7.05±2.9

ZINC000014728394

-7.338

-28.9±19.3

2.7±0.2

17.53±3.1

Natural Ligand

Note. Properties presented are the docking score, MM-GBSA calculation, and
Receptor and Ligand RMSD. 1 Receptor and Ligand RMSD values are averaged
from the last 20 ns of the simulation. Top promising compounds are shown in
bold.
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MM-GBSA Binding Energy Calculations Predict Top Compounds for Nsp15
Inhibition
MM-GBSA was used to calculate the enthalpic terms of the binding
energy as previously described in Chapter 2. The MM-GBSA binding energy
makes several assumptions, including the use of an implicit solvent model. Using
an implicit model assumes the solvent is one continuous medium with a specified
dielectric. This significantly decreases protein-solvent interactions as compared to
an explicit solvent model. These interactions play a non-negligible role in proteinligand binding and should be considered in the future (J. Zhang et al., 2017).
Using this method also removes viscosity from consideration, which speeds up
the conformational search of the solvent. Despite these assumptions, MM-GBSA
provides an accurate prediction of binding energy, while lowering time and
computational costs (Onufriev & Case, 2019).
It is important to note that entropic terms are not considered in these
calculations due to high computational cost. Conformational entropy is known to
contribute significantly (and usually unfavorably) to binding energy (Genheden &
Ryde, 2015) (Singh & Warshel, 2010). There are additional computational
methods available that can be used to accurately predict this contribution
including normal mode analysis. Including entropic terms would offer a more
accurate predicted binding energy.
Analysis of the output from the MD simulations showed four promising
compounds: ZINC000247434422, ZINC000043772626, ZINC000033902452,
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and ZINC000044020013. These compounds were considered to be the most
promising ones because they meet the following criteria: a better (more negative)
docking score than the natural ligand, a low predicted binding energy as
calculated by MM-GBSA, and each remained bound to the protein when the
trajectory stabilized. A two-dimensional structure of each top compound with its
predicted binding energy is presented in Figure 10.

Figure 10
Top Four Compounds and their Predicted Binding Energy

Note. The top four compounds for Nsp15 inhibition were determined by docking
score, predicted binding energy, and the ability to remain bound to the protein
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when the trajectory stabilized. Predicted binding energies according to MMGBSA calculations are listed for each compound in kcal/mol.

RMSD Plots Show the MD Simulation has Stabilized
Binding stability was evaluated by measuring the RMSD values of each
complex throughout the entire simulation. At the end of each simulation, we
expect the RMSD values to converge around a fixed value to confirm
equilibration of the simulation. The values listed for the RMSD of the protein and
ligand in Table 2 are averaged over the last 20 ns where we expect the simulation
to be stabilized. Plots of RMSD values throughout the entire simulation for the
most promising compounds are presented in Figure 11. Small fluctuations of the
RMSD values (between 1-3 Å) are expected throughout the simulation. Larger
fluctuations suggest a larger conformational change and may indicate the ligand
has moved away from the binding site.
All compounds appear to have stable RMSD values for the last 40 seconds
of each simulation except for ZINC000043772626. This compound remained
stable for most of the simulation, then saw a sharp increase within the last 10 ns
with the ligand RMSD measuring 10 Å. The protein RMSD remained stable at
around 4 Å. These findings suggest the ligand may have moved away from the
binding pocket. A longer simulation may be needed to reach equilibration for this
simulation. All other compounds appear stable for the last 40 ns of the simulation
as expected suggesting equilibration.
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Figure 11
RMSD of NSP15 Protein and Top 4 Compounds
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Note. Root Mean Square Deviation (RMSD) plots are presented for the MD
simulation runs of each top protein-ligand complex over the length of the
trajectory. The Cα-RMSD for the protein is shown in dark grey and the ligand
RMSD is shown in light grey. Cα-RMSD is based on initial protein alignment.

MM-GBSA Binding Energy Components
The predicted binding energy calculation combines energy contributions
from non-covalent interactions including Van der Waals, hydrophobic, and
electrostatic terms. The predicted binding energy contribution from each of these
terms is presented in Table 3. These terms are also rewarded by the Glide
docking scoring function, so it is expected that compounds with a favorable (more
negative) docking score will also have a favorable predicted binding energy. An
example of this relationship is shown by compound ZINC000247434422 which
presented the most favorable binding energy at -76.5±6.7 kcal/mol and one of the
highest docking scores at -9.7. The hydrophobic term provided the greatest
contribution to the total binding energy at -40.7±2.3 kcal/mol with an additional
heavy contribution from the Van der Waals term at -35.3±0.7 kcal/mol. These
contributions to the predicted binding energy can be better understood when we
examine them separately.
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Table 3
The MM-GBSA Binding Energy Calculation Components Including the Van der
Waals, Hydrophobic, and Electrostatic Terms are Presented
Zinc ID

Hydrophobic
(kcal/mol)

Natural Ligand

Van der
Waals
(kcal/mol)
-22.8±2.2

-7.6±1.4

1.9±1.4

ZINC000013545806

-35.1±2.8

-43.4± 2.0

11.2±1.5

ZINC000004096690

-16.6±5.5

-7.0±1.2

2.5±1.1

ZINC000247434422

-35.3±0.7

-40.7±2.3

-0.5±5.2

ZINC000004095545

-2.7±3.4

-1.1±1.3

1.2±1.6

ZINC000030690671

-11.5±4.6

-17.1±8.1

-0.1±7.1

ZINC000004096060

2.2±3.3

-1.2±1.8

-7.7±4.6

ZINC000043898683

-24.0±9.1

-23.6±10.2

9.4±2.4

ZINC000043772626

-25.9±4.1

-24.5±2.1

3.0±5.9

ZINC000257311522

-18.0±3.5

-13.3±5.8

-9.9±2.7

ZINC000002573902

-21.6±2.5

-13.9±1.7

1.8±1.4

ZINC000097814854

-33.3±4.0

-16.8±3.8

10.0±2.7

ZINC000005811925

-10.2±1.7

-2.6±0.8

-7.0±7.5

ZINC000095447896

-22.1±4.2

-12.0±4.4

3.6±3.2

ZINC000033902452

-23.5±4.8

-16.9±0.3

-8.6±6.9

ZINC000044020013

-29.3±2.2

-20.7±1.0

0.0±4.6

ZINC000584892418

-15.3±4.5

-12.1±2.9

-0.8±6.1

ZINC000257288396

-18.5±6.6

-12.6±1.9

-4.9±4.8

ZINC000009716294

-26.3±4.4

-16.6±2.0

3.7±3.9

ZINC000014728394

-19.9±12.4

-12.4±7.3

3.4±2.0

Note. Top promising compounds are shown in bold

32

Electrostatic
(kcal/mol)

As described in chapter 2, the Van der Waals term is the sum of Van der
Waals, π-π stacking, and self-contact energies. The hydrophobic term is measured
alone while the electrostatic term is the sum of energy contributions made by
Coulomb interactions, Hydrogen bonds, and general born solvation energies. A
breakdown of these terms allows us to further understand how the ligand interacts
with the binding pocket.
The Van der Waals and hydrophobic terms of the predicted binding
energy equation dominate ligand binding for these compounds. In Table 3, top
compounds all had large contributions from both of these terms. It is expected that
Van der Waals interactions to contribute significantly to the binding energy due to
the number of these interactions involved in molecular recognition (L. Li et al.,
2015). Hydrophobic interactions are extremely valuable and frequent in
supporting ligand binding. These interactions drive nonpolar interactions to
displace water molecules from interacting surfaces within the binding pocket
(Wermuth et al., 2015).
There were minimal favorable and unfavorable contributions to the total
binding energy from the electrostatic term in all cases as expected. The energy
from hydrogen bonds can vary in intermolecular interactions, and in these
simulations their contributions were very small. The contribution from Coulombic
energy and binding solvation are similar in magnitude, but opposite in their signs
leaving the sum of the total electrostatic contribution to be a small number of
either positive or negative value. It is important to note that the electrostatic term
is highly dependent on the parameters of the simulation including the force field
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chosen, the dielectric constant of the protein and the refinement of the proteins
structure (Talley et al., 2008).
The Protein Cα RMSF Confirms the Stability of Compound Binding by Residue
Residue fluctuation was measured throughout the simulation and is
presented by RMSF values in Figure 12. Higher RMSF values indicate more
fluctuation of amino acids throughout the MD simulation. It is common for the N
and C terminal tails of the protein to fluctuate significantly, and we observe that
for all simulations. We expect that secondary structures (alpha helices and beta
strands) remain more rigid with lower RMSF values, while loop regions have a
higher rate of fluctuation throughout each simulation.
Residues fluctuated similarly for each compound and the natural ligand
with a differing fluctuation observed for the complex with compound
ZINC000044020013 in residues 13-25. These residues are a part of a loop region
between an alpha helix structure and a beta strand. An amino acid sequence of
Nsp15 including secondary structure assignments is presented as Appendix
Figure 1. This particular compound relies heavily on its binding interaction with
only its carboxylic acid group. Its binding may not stabilize this loop region as
well as the other top compounds allowing for some additional protein flexibility.
Compound ZINC000043772626 also shows additional fluctuation between
residues 103 through 110 which is a loop region.
Amino acids interacting within the binding pocket, including His235,
His250, Lys290, Ser 294, Thr341, Tyr343, appear stable in each simulation with
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RMSF values under 3 Å. As expected, loop regions show the most flexibly, this is
apparent in regions 45-52 and 256-265 where RMSF values reach approximately
5.5 Å.
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Figure 12
Residue Fluctuation Plotted by RMSF
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Note. The residue fluctuation plotted by RMSF during binding with each top compound
(Cyan: Natural Ligand, Orange: ZINC000247434422, Grey: ZINC000043772626,
Yellow: ZINC000033902452, Dark Blue: ZINC000044020013). Residues fluctuated
similarly throughout the simulation for all compounds with an exception in residues 13
through 25 for ZINC000044020013.

Simulation Interaction Diagrams Reveal Key Binding Residues for Top Compounds
Key residues supporting compound binding to Nsp15 for at least 30 % of the
simulation were identified by the Desmond simulation interaction diagram (Figure 13).
These interactions are expected to agree with docking score and MM-GBSA binding
energy prediction value. As shown previously in Table 3, most of the predicted binding
energy is composed of the Van der Waals and hydrophobic terms so we expect
interactions to support these energy contributions. Most of the interactions displayed in
the simulation diagrams were driven by hydrophobic or polar interactions with the
binding pocket which agrees with these findings. The residues responsible for these
interactions within the binding pocket are His235, His250, Lys290, Ser 294, Thr341, and
Tyr343.
For ZINC000247434422, key interactions include polar interactions through
water molecules with His250 and Ser 294 for 41% and 39% of the simulation,
respectively. Hydrophobic interactions with residues Leu346 and Pro344 were
maintained for 42% and 46% of the simulation respectively. This compound had the
highest docking score and predicted binding energy which was supported in large by its
hydrophobic and Van der Waals energy contributions.
Interactions supporting ZINC000043772626 included a positive charge with
Lys290 for 40% and 36% of the simulation with two separate oxygens. A polar
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interaction with Asn278 for 35% of the simulation, and hydrophobic interactions with
waters and Leu 346 (37%) and Val292 (34%) also contributed to the compounds binding
to Nsp15. This compound had similar contributions from hydrophobic and Van der
Waals terms.
ZINC000033902452 has a positively charged interaction with Lys290 for 69% of
the simulation and Lys 345 for 37% of the simulation. Hydrophobic interactions for
ZINC000033902452 include: Val292 (58%), Trp333 (62%), Leu346 through water for
51%, and Tyr343 through interactions with two separate waters for 40% and 36% of the
simulation. Polar interactions include His250 through a water for 35% and Ser294 for
57% of the simulation. Several interactions between this compound and the binding
pocket are hydrophobic which is reasonable as the predicted binding energy of this
compound was supported heavily by its hydrophobic term.
Compound ZINC000044020013 has a positively charged interaction with Lys290
with two oxygens for 37% and 32% of the simulation. Gly248 maintained interaction
with Nsp15 for 36% of the simulation. This compound had the least amount of
interaction with the binding pocket. This resulted in a less favorable predicted binding
energy when compared to the other top compounds.
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Figure 13
2D Ligand Interaction Diagrams of Top 4 Compounds
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Note. 2D ligand interaction diagrams from the MD trajectory for the top four
compounds show the interactions supporting binding to Nsp15. The residues shown
interacted with each ligand for a minimum of 30% of the simulation time.

SwissADME Predicts Important Drug Discovery Parameters
Important ADME properties for each compound were predicted using the
SwissADME server. When evaluating a compound for use in a drug, we must
consider how it will reach its target and assess absorption, distribution,
metabolism, and excretion within the body. Properties highlighted in our search
were GI absorption, blood brain barrier permeability, Lipinski rule of 5 violations,
Cytochrome P450 enzyme inhibition, PAINS alerts, and Brenk alerts.
Gastrointestinal absorption and blood brain barrier permeability is
predicted by the Swiss ADME server using the Brain Or IntestinaL EstimateD
permeation (BOILED-Egg) method. This method measured the lipophilicity (by
Log P) and polarity (by polar surface area (PSA) of each compound and sorts
them based on their likelihood to be passively absorbed by the gastrointestinal
tract or passively diffused through the blood brain barrier. Parameters of the
BOILED -Egg considered good gastrointestinal absorption are PSA lower than
142 Å and log P between −2.3 and +6.8 (Daina & Zoete, 2016). Parameter
considered good for blood brain barrier permeability are a PSA <79 Å and a
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lipophilic log P from 0.4 to 6.0. SARS-CoV-2 and other coronaviruses are most
commonly detected in the upper airways, lungs, mouth, and the gastrointestinal
tract so blood brain barrier permeability is not necessary for reaching Nsp15
(Trypsteen et al., 2020). We are most interested in gastrointestinal tract absorption
for this study as that is promising for an oral drug which simplifies delivery.
Lipinski’s rule of five helps determine if a drug meets a set of standards
known to allow drug absorption and permeability. These five rules include a
molecular weight less than 500 daltons, a calculated octanol-water partition
coefficient (LogP) less than or equal to 5, includes hydrogen bonding acceptors
(less than or equivalent to 10), as well as hydrogen bonding donors less than or
equivalent to 5 (Benet et al., 2016). Lipinski’s rules consider any compound with
more than one violation to be a poor candidate for drug use.
The Swiss ADME server also screens compounds for their ability to
inhibit top CYP enzymes. Cytochrome P450 enzymes are isoenzymes that play a
key role in drug elimination (Daina et al., 2017). Inhibition of the enzymes can
lead to drug-drug interactions which may result in toxic or other adverse effects
caused by low clearance of the drug (Daina et al., 2017). Understanding the
potential for a new drug to inhibit the cytochrome P450 enzymes plays an
important role in predicting potential interactions between drugs and drug
excretion.
Pan Assay Interference Compounds (PAINS), bind non-specifically to
drug targets. These compounds are known to cause false positives in high
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throughput virtual screenings. Lack of PAINS alerts suggest a good outlook for
these compounds to bind specifically to their target in drug form (Baell &
Holloway, 2010).
Brenk alert determines lead-likeness of a molecule and focuses on
physiochemical boundaries. Leads may be subject to chemical modifications to
optimize the compound which may increase the size of the molecule or its
lipophilicity. In anticipation of these modifications, leads should begin smaller in
size and less hydrophobic than other molecules.
Results of the Swiss ADME predictions are listed in Table 4. Two
compounds had good gastrointestinal absorption: ZINC000247434422 and
ZINC000043772626 while none displayed the ability to permeate the blood brain
barrier. The top four compounds for Nsp15 do not show potential to be inhibitors
for four of the five subtypes of cytochrome P450 enzymes (CYPs) including
CYP1A2, CYP2C19, CYP2C9, CYP2D6 (McDonnell, PharmD, BCOP & Dang,
PharmD, BCPS, 2013). Two compounds (ZINC000247434422 and
ZINC000043772626) show potential to inhibit CYP3A4. Compounds had no
Lipinski rule of five violations, PAINS or Brenk alerts.
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Table 4
The Predicted ADME Properties for the Top 4 Best Compounds by the SwissSimilarity Server are Presented
Compound

GI
BBB
absorption Permeant

Lipinski CYP1A2 CYP2C19 CYP2C9
Rule
Violations

CYP2D6 CYP3A4 PAINS Brenk
Alerts Alerts
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ZINC000247434422

+

-

-

-

-

-

-

+

-

-

ZINC000043772626

+

-

-

-

-

-

-

+

-

-

ZINC000033902452

-

-

-

-

-

-

-

-

-

-

ZINC000096232566

-

-

-

-

-

-

-

-

-

-

Note. Predicted properties include gastrointestinal absorption, blood brain barrier permeability, Cytochrome P450 enzyme inhibition, Lipinski
Rule of five violations, PAINS alerts, and Brenk alerts + indicates high GI absorption, BBB permeability, a Lipinski rule violation, inhibition of a
cytochrome P450, or a PAINS or Brenk alert. - indicates low GI absorption, no BBB permeability, no Lipinksi Rule Violations, no CYP
inhibition, and no PAINS or Brenk alerts.

Based on the SwissADME server screening, all four top compounds
remain promising. The two compounds without high gastrointestinal absorption
(ZINC000033902452 and ZINC000096232566) would need further consideration
for a delivery method as an oral administration may not be suitable. Interactions
between CYP3A4 and compounds ZINC000247434422 and ZINC000043772626
should be further investigated. Several effective antiviral drugs are inhibitors of
CYP3A4, it is just important to consider toxicity levels of the drug and any other
potential drug-drug interactions.
Conclusion
We have presented four promising compounds targeting the Nsp15 protein
of SARS-CoV-2. The results of our Molecular docking and MD simulations
conclude that each top compound has a favorable predicted binding energy to the
Nsp15 active site. The compound performing best through all analyses for Nsp15
was ZINC000247434422 with the most favorable predicted binding energy at 76.5±6.7 kcal/mol. The SwissADME screening allowed us to identify preliminary
parameters suggesting that these compounds may succeed in drug form. Each
compound remains a candidate for further experimental validation as a Nsp15
small molecule inhibitor.
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Chapter 4
Molecular Docking and Molecular Dynamics Simulation of Inhibitors Targeting
Mpro
Introduction
The Mpro of Coronaviruses plays a significant role in processing viral replication
making it a potential target for a small molecular inhibitor. In this chapter, I present our
high throughput virtual screening of ZINC 15. Eight promising compounds were
identified for Mpro Molecular dynamics simulation allowed us to predict the binding
energies (calculated by MM-GBSA) for these compounds and further understand the
interactions supporting binding to their target. Using the SwissADME server we were
able to identify structurally based ADME properties that determine the likelihood of our
compounds to perform successfully as drugs.
Molecular Docking
Natural Ligand Docking
Using Glide docking software in Maestro, we measured the binding score of the
natural ligand of the Mpro (Figure 14). The binding score of the natural ligand to the
binding site used in our molecular docking and molecular dynamics simulations was
calculated at -9.607 kcal/mol. When evaluating molecules for docking, we originally
searched for compounds with preliminary docking scores better (more negative) or
equivalent to this value. Most compounds in the high throughput virtual screening did not
meet these criteria so compounds with a Glide docking score less than -8.4 kcal/mol were
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considered. Values with docking scores close to the natural ligand score are acceptable as
there is variability in the scoring function.

Figure 14
Mpro in Complex with its Natural Ligand and 2D Structure

Note. A. Mpro is shown in complex with its natural ligand (PDB:6LU7). B. The twodimensional structure of the natural ligand of Mpro is presented.
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High Throughput Virtual Screening and Molecular Docking
From our high throughput virtual screening of the DrugBank and Zinc15
database, 31 molecules were selected from the Zinc15 database for preliminary molecular
docking to Mpro using structure PDB:6LU7. The compounds listed in Table 5 were found
to have an initial docking score greater than or equal to -8.4 kcal/mol. After eliminating
molecules with high structure similarity, remaining compounds selected by docking
score, were further evaluated by induced fit docking. Docking scores selected for further
consideration ranged from -8.4 kcal/mol to -10.1 kcal/mol. These compounds were next
evaluated by molecular dynamics simulation.
Molecular Dynamics Simulation
Molecular dynamics simulation was performed to evaluate binding of hit
compounds to Mpro. Output of the MD simulations included docking scores, MM-GBSA
free energy, and protein and ligand RMSD. Results of this simulation are presented in
Table 5.
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Table 5
Properties of the Top 31 Compounds from Molecular Docking and MD
Simulations are Presented
Zinc ID

Docking Score
(kcal/mol)

MM-GBSA
(kcal/mol)

Receptor
RMSD1 (Å)

Ligand
RMSD1 (Å)

Natural Ligand

-8.4

-70.08 ± 12.5

1.6±0.1

5.1±1.0

ZINC000004600917

-10.1

-43.9 ± 10.6

2.7±0.1

3.1±0.4

ZINC000057312352

-9.4

-73.0 ± 13.0

2.1±0.1

4.3±0.9

ZINC000000090720

-9.4

-51.3 ± 9.0

2.1±0.2

8.8±0.6

ZINC000020988539

-9.3

-54.8 ± 6.4

2.3±0.1

6.3±0.3

ZINC000004899522

-9.1

-55.8 ± 8.4

3.0±0.2

5.9±0.3

ZINC000253630002

-9.1

-62.9 ± 7.9

1.9±0.2

6.0±0.2

ZINC000014728050

-9.1

-54.5 ± 6.9

2.7±0.1

6.6±0.5

ZINC000064568387

-9.0

-68.8 ± 8.4

2.3±0.1

10.4±0.4

ZINC000004897405

-9.0

-62.3 ± 13.6

3.2±0.2

7.7±0.5

ZINC000223270144

-9.0

-61.7 ± 11.4

2.5±0.2

9.7±0.4

ZINC000096447388

-8.9

-68.3 ± 14.1

2.7±0.1

7.2±0.3

ZINC000012119172

-8.8

-39.2 ± 9.4

2.6±0.1

17.8±0.5

ZINC000000121038

-8.8

-51.6 ± 9.0

2.0±0.1

5.4±0.4

ZINC000070216736

-8.8

-40.3 ± 8.2

6.7±0.4

8.3±0.6

ZINC000663523562

-8.8

-72.6 ± 12.1

2.7±0.2

9.3±1.5

ZINC000005273576

-8.7

-44.5 ± 14.5

3.0±0.1

8.3±2.5

ZINC000064568512

-8.7

-83.4 ± 8.5

3.1±0.1

2.4±0.2

ZINC000000632530

-8.7

-59.7 ± 13.9

2.8±0.3

12.2±0.6

ZINC000261493176

-8.7

-33.6 ± 15.7

2.7±0.1

35.8±2.7

ZINC000426359607

-8.7

-69.0 ± 13.2

2.7±0.2

8.7±0.3

ZINC000263585674

-8.6

-69.1 ± 10.7

2.3±0.1

9.2±0.3

ZINC000057774900

-8.6

-56.5 ± 12.6

3.1±0.2

10.5±0.6
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Zinc ID

Docking Score
(kcal/mol)

MM-GBSA
(kcal/mol)

Receptor
RMSD1 (Å)

Ligand RMSD1
(Å)

ZINC000089440373

-8.6

-73.2 ± 12.2

2.3±0.1

9.4±0.6

ZINC000019341151

-8.6

-84.5 ± 11.9

2.2±0.2

3.1±0.4

ZINC000193716208

-8.6

-56.7 ± 21.2

3.2±0.2

24.4±4.3

ZINC000008876585

-8.5

-63.1 ± 7.7

2.9±0.1

4.8±0.4

ZINC000012165443

-8.5

-85.6 ± 15.3

2.7±0.1

10.2±0.8

ZINC000012990014

-8.5

-43.0 ± 9.4

2.6±0.2

3.0±0.3

ZINC000001547992

-8.5

-72.2 ± 9.5

2.5±0.2

2.9±0.3

ZINC000015680255

-8.4

-71.8 ± 16.4

2.1±0.1

6.5±0.5

ZINC000005553602

-8.4

-57.8 ± 12.3

2.1±0.1

7.4±0.6

Note. Properties including the docking score, total binding energy as calculated by
MM-GBSA, and the RMSD for the ligand and protein. 1 Receptor and Ligand
RMSD values are averaged from the last 20 ns of the simulation. Top promising
compounds are shown in bold

Analysis of the output from the MD simulation showed eight promising
compounds: ZINC000057312352, ZINC000663523562, ZINC000064568512,
ZINC000089440373, ZINC00019341151, ZINC000012165443,
ZINC000001547992, and ZINC000015680255. These compounds and their
docking scores are presented in Figure 15. Each compound had a docking score
higher than -8.4 kcal/mol, a low predicted binding energy, and remained bound to
the protein after the trajectory stabilized.
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Figure 15
Top 8 Compounds and their Predicted Binding Energy
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Note. Top eight compounds for Nsp15 inhibition were determined by docking score,
predicted binding energy, and the ability to remain bound to the protein when the
trajectory stabilized. Predicted binding energies according to MM-GBSA calculations are
listed for each compound.

RMSD Plots Show the Simulation has Stabilized
Binding stability was evaluated by measuring the RMSD values of each complex
throughout the entire simulation. The values listed for the RMSD of the protein and
ligand in Table 5 are averaged over the last 20 ns. As previously described in chapter 3,
we expect the RMSD values to converge around toward the end of the simulation to
confirm equilibration. Plots of RMSD values throughout the entire simulation for the
eight most promising compounds are presented in Figure 16. Small fluctuations of the
RMSD values (between 1-3 Å) are expected throughout the simulation. Larger
fluctuations suggest a larger conformational change for the protein or may indicate the
ligand has moved away from the binding site.
The RMSD values of each complex throughout the simulation is presented in
figure 16. For all simulations, the protein RMSD remained stable. The RMSD for
compounds ZINC000057312352, ZINC000064568512, ZINC00019341151,
ZINC000001547992, and ZINC000015680255 remained stable throughout the simulation
which suggests the ligand is stable within the binding pocket of the protein. Compounds
ZINC000663523562, ZINC000089440373, and ZINC000012165443 saw a large change
in the ligand RMSD value towards the end of the trajectory. A longer simulation may
allow us to see if stabilization occurs.
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Figure 16
RMSD of Mpro and Top 8 Compounds
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Note. Root Mean Square Deviation (RMSD) plots are presented for the MD simulation
runs of each top protein-ligand complex over the length of the trajectory. The Cα-RMSD
for the protein is shown in dark grey and the ligand RMSD is shown in light grey. CαRMSD is based on initial protein alignment.
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MM-GBSA Binding Energy Components
The MM-GBSA predicted binding energy calculation combines energies
contributed from the Van der waals, hydrophobic, and electrostatic terms. The predicted
binding energy from each of these terms is presented in Table 6. These terms are
rewarded by the Glide docking score scoring function, so it is reasonable to expect that
compounds with a favorable (more negative) docking score will also have a favorable
predicted binding energy. A breakdown of these terms allows us to further understand
how the amino acids within the binding pocket interact with the ligand.
Ligand interactions with the Mpro binding pocket were supported heavily by the
Van der Waals term. As previously discussed, the Van der Waals term is the sum of
energy contribution made by Van der Waals interactions, pi-pi stacking, and self-contact
energies. The hydrophobic term is measured alone while the electrostatic term is the sum
of energy contributions made by Coulomb interactions, hydrogen bonds, and general
Born solvation energies. The Van der Waals and hydrophobic terms of the predicted
binding energy equation are the largest contributors for all top compounds. Electrostatic
contributions were minimal and mostly unfavorable for this target.
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Table 6
The MM-GBSA Binding Energy Calculation Components Including the Van der Waals,
Hydrophobic, and Electrostatic Terms are Presented

Zinc ID

Van der Waals
(kcal/mol)

Hydrophobic
(kcal/mol)

Natural Ligand

-49.0 ± 5.2

-31.1 ± 5.2

10.2 ± 4.8

ZINC000004600917

-27.7 ± 4.6

-16.7 ± 2.8

0.5 ± 6.3

ZINC000057312352

-46.5 ± 7.1

-31.4 ± 5.5

4.9 ± 5.8

ZINC000000090720

-32.0 ± 4.1

-17.9 ± 2.2

-1.5 ± 6.5

ZINC000020988539

-36.4 ± 5.9

-24.5 ± 3.6

6.1 ± 4.6

ZINC000004899522

-33.8 ± 4.9

-24.5 ± 3.4

2.5 ± 5.8

ZINC000253630002

-42.7 ± 4.6

-27.6 ± 3.0

7.3 ± 3.3

ZINC000014728050

-31.7 ± 2.6

-21.1 ± 2.4

-1.8 ± 5.8

ZINC000064568387

-41.9 ± 5.0

-35.2 ± 5.3

8.4 ± 3.2

ZINC000004897405

-43.1 ± 5.4

-27.2 ± 4.9

7.9 ± 8.0

ZINC000223270144

-38.1 ± 3.8

-23.9 ± 3.6

0.3 ± 6.5

ZINC000096447388

-39.2 ± 6.7

-30.1 ± 7.5

0.9 ± 5.2

ZINC000012119172

-31.7 ± 6.2

-17.5 ± 4.8

10.0 ± 2.8

ZINC000000121038

-33.3 ± 5.4

-25.1 ± 4.0

6.7 ± 3.1

ZINC000070216736

-26.6 ± 5.5

-16.7 ± 2.8

3.0 ± 3.4

ZINC000663523562

-42.0 ± 6.3

-34.5 ± 4.5

4.0 ± 5.1

ZINC000005273576

-29.1 ± 9.6

-17.2 ± 6.2

1.9 ± 7.8
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Electrostatic
(kcal/mol)

Zinc ID

Van der Waals
(kcal/mol)

Hydrophobic
(kcal/mol)

Electrostatic
(kcal/mol)

ZINC000064568512

-48.9 ± 4.9

-44.0 ± 3.8

9.5 ± 4.4

ZINC000000632530

-35.0 ± 8.0

-31.0 ± 6.5

6.3 ± 2.3

ZINC000261493176

-21.8 ± 9.4

-16.4 ± 8.1

4.6 ± 3.2

ZINC000426359607

-40.4 ± 6.8

-33.9 ± 7.1

5.4 ± 4.4

ZINC000263585674

-44.2 ± 5.9

-31.3 ± 4.8

6.4 ± 4.5

ZINC000057774900

-35.7 ± 6.7

-25.1 ± 5.0

4.2 ± 5.1

ZINC000089440373

-41.7 ± 6.8

-30.0 ± 5.3

-1.6 ± 6.0

ZINC000019341151

-51.8 ± 6.1

-36.4 ± 5.3

3.6 ± 5.1

ZINC000193716208

-28.8 ± 9.2

-24.5 ± 9.6

-3.4 ± 5.6

ZINC000008876585

-44.2 ± 5.0

-25.3 ± 4.1

6.4 ± 4.6

ZINC000012165443

-51.6 ± 8.2

-39.2 ± 6.9

5.2 ± 3.0

ZINC000012990014

-31.3 ± 4.0

-17.3 ± 4.0

5.7 ± 4.7

ZINC000001547992

-51.3 ± 7.6

-24.0 ± 3.1

3.0 ± 4.7

ZINC000015680255

-45.0 ± 8.0

-27.4 ± 8.7

0.6 ± 4.5

ZINC000005553602

-36.1 ± 5.8

-26.2 ± 7.3

4.5 ± 3.3

Note. Top promising compounds are shown in bold.
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The Protein Cα Root Mean Square Fluctuation Confirms the Stability of Compound
Binding.
Residue fluctuation was measured throughout the simulation and is presented by
RMSF values in Figure 17. Higher RMSF values indicate more fluctuation of amino
acids throughout the MD simulation. We see the largest fluctuations at the N and C
terminals which is expected. Residues fluctuated similarly for each compound and the
natural ligand with larger fluctuations found in loops between secondary structures which
was observed in residues 40-53, 140-148, 152-155, 165-170, 180-200, and 275-290. An
amino acid sequence of the Mpro including secondary structure assignments is presented
as Appendix Figure 2 which allows us to identify these loop regions. Key amino acids
interacting within the binding pocket including Ser 46, leu141, Asn 142, Glu 166,
Pro168, Ala191, Thr190, and Gln189 appear stable with RMSF values under 3 Å.
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Figure 17
Residue Fluctuation Plotted by RMSF
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Note. Residue fluctuation plotted by RMSF (Cyan: Natural Ligand, Orange: ZINC000057312352, Light Grey: ZINC000663523562,
Yellow: ZINC000064568512, Light Blue: ZINC000089440373, Green: ZINC00019341151 Dark Blue: ZINC000012165443 Red:
ZINC000001547992 Dark Grey: ZINC000015680255)

Simulation Interaction Diagrams Reveal Key Binding Residues for Top Compounds
Key residues supporting compound binding to Nsp15 for at least 30 % of the
simulation were identified by the Desmond simulation interaction diagram (Figure 18).
These interactions are expected to agree with docking score and MM-GBSA binding
energy prediction value. As shown in Table 6, most of the predicted binding energy is
composed of the Van der Waals and hydrophobic terms. Most of the interactions
displayed in the simulation diagrams for Mpro were driven by hydrophobic, polar, and
charged interactions. This agrees with known characteristics of residues found within the
binding pocket including: Cys145, His4, Ser 46, leu141, Asn 142, Glu 166, Pro168,
Ala191, Thr190, and Gln189
Interactions supporting ZINC000057312352 binding include hydrophobic
interactions with Met49 and Met165. Positive charge interactions included His41 for 34%
of the simulation as well as Gln189 for 35% of the simulation. This compound had the
most favorable predicted binding energy, with most of its energy contributions coming
from the Van der Waals term.
ZINC000663523562 has a single positive charge interaction with Gln189 for 34%
of the simulation. ZINC000064568512 has a negatively charged interaction with Asp187
for 30% while most of the compound remains solvent exposed. These compounds also
received most of their predicted binding energy contribution from the Van der Waals
term.
Compound ZINC000089440373 interacts with the Mpro via positively charged
interactions with His41 (37%) and Thr45 (42%) and negative charged interactions with
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Glu166 through an interaction with a water molecule (39%) and Asp187 (35%).
ZINC000019341151 interacts with Gly143 96 % of the simulation. Positively charged
interactions supporting binding include with Ser144 (35%) and His164 (53%). A single
negatively charged interaction with Glu166 through an interaction with a water molecule
takes place for 38% of the simulation.
Binding of ZINC000012165443 is supported by two hydrophobic interactions
with Phe185 and Val186 for 58% of the simulation. Other residues involved in binding
include a polar interaction with His164 (34%) and a positive charged interaction with
Arg40 (44%). Half of this compound remains solvent exposed.
ZINC000001547992 binding energy is mostly supported by Van der Waals
interactions. This compound has two negatively charged interactions with Asp187 and
Glu166. Asp187 interacts with the ligand directly for 50% of the simulation and through
a water bridge for 32% of the simulation. Glu166 interacts with the ligand directly for
82% of the simulation and through an interaction with water for 45% of the simulation.
The compound also has two polar charged interactions with His41 (30%) and His164
(33%).
ZINC000015680255 has one hydrophobic interaction with Cys145 for 40% of the
simulation. Three polar interactions with the protein include His41 in two separate areas
of the compound for 52% and 47% of the simulation, Ser144 for 40% of the simulation,
and Gln189 for 37% of the simulation. There is a single negatively charged interaction
with Glu166 for 98% of the simulation. The binding energy for this compound is also
supported heavily by Van der Waals interactions.
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Figure 18
2D Ligand Interaction Diagrams of Top 8 Compounds
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Note. 2D ligand interaction diagrams from the MD trajectory for top eight compounds
show the interactions supporting binding of top compounds. Residues displayed interacted
with each ligand for a minimum of 30% of the simulation time.

SwissADME Predicts Important Drug Discovery Parameters
Predicted ADME properties including gastrointestinal absorption, blood brain
barrier permeability, Lipinski rule of 5 violations, inhibition of five cytochrome P450
enzymes, PAINS alerts, and Brenk alerts for the top eight compounds are presented in
Table 7. A full description of each of these properties was presented previously in
Chapter 3.
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Table 7
The Predicted ADME Properties for the Top 8 Best Compounds by the SwissSimilarity Server are Presented
Note. Predicted properties include gastrointestinal absorption, blood brain barrier permeability, Cytochrome P450 enzyme inhibition,
Compound

GI
BBB
absorption Permeant

Lipinski CYP1A2 CYP2C19 CYP2C9
Rule
Violations
+
-

+

+

+

-

-

-

ZINC000663523562

+

-

-

-

+

+

+

+

-

-

ZINC000064568512

+

-

-

+

+

+

+

+

-

-

ZINC000089440373

+

-

-

-

+

+

-

+

-

-

ZINC000019341151

+

-

-

+

+

+

+

+

-

-

ZINC000012165443

+

-

-

-

+

+

+

+

-

-

ZINC000001547992

-

-

+

-

-

-

-

-

-

-

ZINC000015680255

+

-

-

-

+

+

+

+

-

-
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ZINC000057312352

CYP2D6 CYP3A4 PAINS Brenk
Alerts Alerts

Lipinski Rule of five violations, PAINS alerts, and Brenk alerts. + indicates high GI absorption, BBB permeability, a Lipinski rule
violation, inhibition of a cytochrome P450, a PAINS alert, or a Brenk alert. - indicates low GI absorption, no BBB permeability, no
Lipinksi Rule Violations, no CYP inhibition, and no PAINS or Brenk alerts.

All compounds show high intestinal absorption properties apart from
ZINC000001547992. This suggests most compounds would be suitable for oral delivery.
Compound ZINC000057312352 was the only compound that showed potential for blood
brain barrier permeability. As previously discussed, SARS-CoV-2 and other
coronaviruses are more commonly found in the upper airways, lungs, mouth, and the
gastrointestinal tract so blood brain barrier permeability is not necessary.
Compounds targeting the Mpro show varying potential to be inhibitors for the five
subtypes of cytochrome P450 enzymes (CYPs) including CYP1A2, CYP2C19, CYP2C9,
CYP2D6, and CYP3A4. Two compounds, ZINC000064568512 and
ZINC000019341151, show potential to inhibit all five of the CYPs in this analysis. It is
likely these compounds would have trouble being metabolized and would likely interact
with several other drugs which raises concern. Compounds ZINC000663523562,
ZINC000012165443, and ZINC000015680255 inhibit four out of the five CYP’s
presented which is also concerning.
The top compounds presented did not have any Lipinski rule of five violations
apart from ZINC000001547992 which has one violation. This compound has more than
ten hydrogen bond acceptors. One Lipinski rule violation does not entirely rule out the
potential for this compound to work as a drug. There were no PAINS or Brenk alerts for
any of the compounds.
In summary, compounds that show the ability to inhibit several CYP enzymes including
ZINC000064568512, ZINC000019341151, ZINC000663523562, ZINC000012165443,
and ZINC000015680255 require further examination to understand if they can be
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metabolized in the body. These compounds should also be evaluated for potential drugdrug interactions. Two compounds, ZINC000057312352 and ZINC000001547992, look
the most promising in their ability to work in drug form.
Conclusion
We have presented eight promising compounds targeting the Mpro of SARS-CoV2. The results of our Molecular docking and MD simulations conclude that each top
compound has a favorable predicted binding energy to the Mpro active site. SwissADME
screening allowed us to identify any preliminary signs that these compounds may not
succeed in drug form. Two compounds: ZINC000057312352 and ZINC000001547992
look the most promising with favorable binding energies and good predicted ADME
properties. RMSD and RMSF values support stability of these compounds interacting
with the Mpro binding pocket.
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Chapter 5
Conclusion and Future Directions
Conclusion
Since March of 2020 when SARS-CoV-2 was declared a pandemic, we have
experienced the effects of this deadly virus across the globe. The development of
vaccines has allowed us to return to some sense of normalcy, but the threat of a vaccineresistant variant, or another coronavirus remains. A small molecule inhibitor targeting
conserved proteins of coronaviruses may improve the outlook of public health now and in
the future. Our high throughput virtual screening resulted in several promising
compounds for the conserved Nsp15 and Mpro protein targets of coronaviruses.
The compound performing best through all the analyses for Nsp15 was
ZINC000247434422 with the most favorable predicted binding energy at -76.5±6.7
kcal/mol, stability throughout the simulation, and a good outlook on important ADME
properties. The other 3 top compounds also performed well overall and should continue
to be considered for experimental analysis.
The Mpro screening resulted in 8 top compounds for further consideration as
inhibitors. Two compounds, ZINC000057312352 and ZINC000001547992, look the
most promising with favorable binding energies and predicted ability to work in drug
form. RMSD and RMSF values support stability of these compounds interacting with the
Mpro binding pocket. Further assessment is needed to determine whether the other six
promising compounds have potential to work as a small molecule inhibitor for this target.
While their predicted binding energy remains favorable, it is important that the
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compounds remain stable in complex with the target and structurally agree with ADME
property parameters to be used as a drug.
While our results have narrowed down a large search of compounds targeting
Nsp15 and Mpro, further experimental analysis is needed to fully characterize binding of
these compounds to their targets. The entropic terms that were unaccounted for in our
analysis should also be considered in future work.
Future Directions
As previously mentioned, the computational methods used for these projects
neglected the entropic terms of binding energy. To address this, I would consider using
additional computational tools available to estimate the entropic properties of compound
binding. The configurational entropy component of binding can be predicted by normal
mode analysis (NMA) (Forouzesh & Mishra, 2021). NMA calculates vibrational modes
as well as protein flexibility reliably, but at a large computational cost (Alexandrov,
2005). To overcome these steep computational costs, many groups use a truncated
version of their protein target. Using this method with MM-GBSA calculations would
offer a more complete prediction of which compounds bind most favorably.
Statistical approaches for analyzing MD simulations vary but would be useful to
verify these methods in future work. Clustering analyses and principal component
analyses (PCA) are commonly applied. Clustering analyses would allow us to group
similar molecular configurations found in the simulation, into groups in an unbiased
manner (Shao et al., 2007). This method of separation would minimize variance in our
predicted free energy calculations. A principal component analysis of each MD
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simulation could offer insight into which conformational changes in the simulation are
relevant versus those that are simulation-based fluctuations which are unlikely to be
repeated. Repeating MD simulations is unpractical due to time and cost therefore these
analyses are important for identifying outliers in the large amount of data produced by
each simulation.
In addition to considering other computational tools, compounds should be
verified experimentally. Both Nsp15 and Mpro plasmids are commercially available for
recombinant protein production (Altincekic et al., 2021). Each compound presented in
this thesis is also available commercially. Nuclear magnetic resonance (NMR)
spectroscopy would be a powerful tool in quantitatively measuring both binding affinity
and the conformational changes that occur during binding. Chemical shift assignments
are available for both the Nsp15 and Mpro proteins at https://covid19-nmr.de/ making
these experiments even more accessible.
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Appendix
Figure A1
Protein Information for Nsp15 Including the Amino Acid Sequence and Secondary
Structure Assignment

Figure A2
Protein Information for Mpro Including the Amino Acid Sequence and Secondary
Structure Assignment

80

